History Of Gout Research Articles

Gambaran Kadar Asam Urat pada Wanita Usia Menopause di Desa Rancapanggung Kecamatan Cililin

gout attacks women who are generally women at the age of menopause. During menopause, women experience a decrease in the function of the ovaries, resulting in a decrease in the function of the hormone estrogen, so that during menopause, women are susceptible to an increase in uric acid levels in the blood. To find out the description of uric acid levels in menopausal women in the Rancapanggung Village area, Cililin District, West Bandung Regency. The research method used was descriptive observational, the sample consisted of 32 menopausal women in the Rancapanggung Village area, Cililin District, West Bandung Regency. The data collection technique uses a frequency distribution table with direct uric acid examination of menopausal women. The results of the study showed the frequency distribution of uric acid levels in menopausal women, most of the respondents had high uric acid levels because previously most of the respondents had a history of gout. Most respondents had high uric acid levels in the age range 50 years and above.The high levels of uric acid in menopausal women in the Rancapanggung Village area, Cililin District, West Bandung Regency are mostly in the age range 50 years and above.

Prediagnostic Amino Acid Metabolites and Risk of Gout, Accounting for Serum Urate: Prospective Cohort Study and Mendelian Randomization.

Our objective was to prospectively investigate prediagnostic population-based metabolome for risk of hospitalized gout (ie, most accurate, severe, and costly cases), accounting for serum urate. We conducted prediagnostic metabolome-wide analyses among 249,677 UK Biobank participants with nuclear magnetic resonance metabolomic profiling (N = 168 metabolites, including eight amino acids) from baseline blood samples (2006-2010) without a history of gout. We calculated multivariable hazard ratios (HRs) for hospitalized incident gout, before and after adjusting for serum urate levels; we included patients with nonhospitalized incident gout in a sensitivity analysis. Potential causal effects were evaluated with two-sample Mendelian randomization. Correcting for multiple testing, 107 metabolites were associated with incidence of hospitalized gout (n = 2,735) before urate adjustment, including glycine and glutamine (glutamine HR 0.64, 95% confidence interval [CI] 0.54-0.75, P = 8.3 × 10-8; glycine HR 0.69, 95% CI 0.61-0.78, P = 3.3 × 10-9 between extreme quintiles), and glycoprotein acetyls (HR 2.48, 95% CI 2.15-2.87, P = 1.96 × 10-34). Associations remained significant and directionally consistent following urate adjustment (HR 0.83, 95% CI 0.70-0.98; HR 0.86, 95% CI 0.76-0.98; HR 1.41, 95% CI 1.21-1.63 between extreme quintiles), respectively; corresponding HRs per SD were 0.91 (95% CI 0.86-0.97), 0.94 (95% CI 0.91-0.98), and 1.10 (95% CI 1.06-1.14). Findings persisted when including patients with nonhospitalized incident gout. Mendelian randomization corroborated their potential causal role on hyperuricemia or gout risk; with change in urate levels of -0.05 mg/dL (95% CI -0.08 to -0.01) and -0.12 mg/dL (95% CI -0.22 to -0.03) per SD of glycine and glutamine, respectively, and odds ratios of 0.94 (95% CI 0.88-1.00) and 0.81 (95% CI 0.67-0.97) for gout. These prospective findings with causal implications could lead to biomarker-based risk prediction and potential supplementation-based interventions with glycine or glutamine.

An idiosyncratic reaction to the synthetic biologic membrane on a surgical wound

Abstract Introduction/Objective Biodegradable temporizing matrix (BTM) is a synthetic polymer used to temporarily close wounds and aid the body in generating new tissue. BTM is applied to a debrided wound.BTM acts as a scaffold aiding the migration of granulation tissue into the matrix. Once the tissue is fully integrated throughout the BTM, the sealing membrane is removed. The matrix slowly deteriorates until fully absorbed at approximately 18 weeks. Methods/Case Report An 80-year-old woman with a past medical history of eczema, rheumatoid arthritis and gout presented with swelling of the left third metatarsal. Imaging showed an abscess which was eventually drained and cultured to show mycobacterium chelone. The patient was started on antibiotics for mycobacterium. On follow up she reported a nodule on left forearm recently increased in size. MRI on 9/28 showed abscess of the dorsal aspect of phalanx. She underwent surgical debridement 10/31 on her finger and the forearm nodule. After debridement a polynovo BTM graft was placed. Histopathology showed skin and subcutaneous tissue with necrotizing granulomas of the finger and the forearm. Cultures and stains for mycobacterium returned negative.The patient was subsequently followed up for wound healing. She reported nodules on the left forearm at the scar from previous surgical site which were biopsied. Histopathology showed granulomatous inflammation, rare foreign body giant cells, and birefringent material. The stains for Ziehl-Neelsen, Fite and Gomori’s Methenamine Silver for Urate Crystals were all negative excluding the possibility of gouty tophi or mycobacterium. Results (if a Case Study enter NA) NA Conclusion The complex history of the patient with mycobacterium, gout, the giant cell reaction and the unique appearing birefringent crystals presented a puzzling problem. Given the negative stain results for mycobacteria and the presence of birefringent (foreign) material, we deem these granulomas most likely an idiosyncratic reaction to the synthetic biologic membrane applied during her prior procedure. There are no known cases of giant cell reaction and similar morphology of birefringent (foreign) material in literature.

Weight Reduction and Target Serum Urate Level: A Longitudinal Study of Annual Medical Examination.

To evaluate associations of weight reduction with serum urate (SU) changes and achieving an SU <6 mg/dl in the real-world setting, outside of specific weight reduction interventions. We analyzed systematically collected data of annual medical examination participants from October 2012 to October 2022. Exposure was weight change (increase or decrease) between two consecutive visits, categorized as minimal (≤0.9 kg, reference), small (1.0-4.9 kg), moderate (5.0-9.9 kg), and large (≥10 kg). Outcomes included SU changes between two consecutive visits and achieving SU <6 mg/dL in hyperuricemic participants (SU ≥7 mg/dL at the prior visit). We identified 58,630 eligible participants (median age 46 years, female 51.3%, overweight 19.4%, median SU 5.3 mg/dL, history of gout and/or hyperuricemia 5.6%) with 336,814 visits over a median of 5.3 years. After adjusting for relevant covariates, linear general estimating equations estimated mean SU changes (95%CI) based on observed weight reductions (vs. minimal changes): small -0.10 (-0.10, -0.09) mg/dL, moderate -0.34 (-0.36, -0.32) mg/dL, and large -0.64 (-0.70, -0.58) mg/dL. In hyperuricemic participants, adjusted relative risks (95%CI) for achieving SU level <6 mg/dL by modified Poisson regression were 1.25 (1.15, 1.37) in small, 2.82 (2.43, 3.27) in moderate, and 5.27 (4.15, 6.70) in large weight reductions, with corresponding NNT of 61.1 for small weight reductions, 8.5 for moderate, and 3.6 for large. Small weight reductions were associated with only small SU changes. Some hyperuricemic participants can achieve the target SU level with moderate to large weight reductions.

8802 A Rare Case Of Symptomatic Hypercalcemia In A Patient With Untreated Chronic Tophaceous Gout

Abstract Disclosure: S. Avula: None. A. Kumar: None. Z.J. Anderson: None. A. Chauhan: None. L.T. LaFave: None. Background: Hypercalcemia is a medical condition with abnormally high serum calcium levels. There are numerous mechanisms for the development of hypercalcemia, but gout is not well documented.Hypercalcemia attributed to Tophaceous gout is a rare phenomenon that is not well studied. Here we report a case of symptomatic hypercalcemia in a patient with a history of untreated tophaceous gout, leading to hypercalcemia and osteolytic lesions. Clinical Case: The patient is a 52-year-old male with a medical history of hypertension, rheumatoid arthritis, and tophaceous gout who immigrated from Tanzania. He presented with two weeks of abdominal pain that acutely worsened the morning of his presentation. He reported a 16-year history of tophaceous gout, for which he had been treated with allopurinol without success. On physical examination polyarticular subcutaneous nodules were present in the bilateral upper and lower extremities, primarily over the joints. There were similar lesions on the buttocks. Initial laboratory evaluation included a complete blood count which was notable for a hemoglobin of 10.3 g/dL (13.1 - 17.5 g/dL). His albumin was normal at 4 g/dl. (3.8 - 5.1 g/dl). Serum calcium was elevated at 12.9 mg/dL (8.8-10.0 mg/dL), with a serum ionized calcium level of 6.52 mg/dL(4.40-5.20 mg/dL). PTH was low at 15.8 pg/mL (16.0 - 65.0 pg/mL), and PTHrP was 2.9 pg/ml (&amp;lt;4.5 pg/ml). Uric acid level on admission was elevated to 11.4 mg/dL (3.4 - 7.0 mg/dL). 1-25 dihydroxy vitamin D elevated at 93.2 pg/mL (19.9 - 79.3 pg/mL). Computed tomography (CT) with intravenous contrast of the chest, abdomen, and pelvis was notable for axillary, pelvic, and inguinal lymphadenopathy concerning for lymphoproliferative or neoplastic processes. Biopsy of right inguinal node biopsy showed benign-appearing lymphoid tissue. Additional findings included multiple lobulated calcified hyperdense foci throughout the subcutaneous and muscular tissues of the buttocks with resorptive changes of the axial skeleton. Spectral CT reconstruction determined these to be uric acid deposits. Radiographs of his extremities were consistent with advanced gouty arthropathy. Infectious work-up was negative. Patient was given 3 liters of 0.9% sodium chloride. He received four doses of Calcitonin (4 units/kg) followed by one dose of Zoledronic acid 5 mg I.V. He was treated with Febuxostat, solumedrol and Azathioprine for his tophaceous gouty arthritis. Conclusion: Hypercalcemia is a commonly encountered yet a very important clinical condition. Parathyroid and malignant etiologies of hypercalcemia account for approximately 90% of cases of hypercalcemia. Gout as the inciting factor for developing hypercalcemia is a rarely documented phenomenon. This case highlights hypercalcemia as an unusual yet severe manifestation of untreated chronic gout and demonstrates the need for additional studies and reviews. Presentation: 6/2/2024

12394 "Sugar And Tumors: A Case Report On New-onset Diabetes In Metastatic Pheochromocytoma With Elevated Dopamine Levels"

Abstract Disclosure: B. Agrawal: None. V. mehta: None. R. naseem: None. M. Renzu: None. R. rashid: None. Introduction: Metastatic pheochromocytoma is a rare neuroendocrine tumor with potential complication of new-onset diabetes mellitus (DM). We present a case highlighting the challenges in managing a patient with metastatic pheochromocytoma and concurrent DM. Case presentation: A 66-year-old male with a history of hypertension and gout initially presented in 2010 with an adrenal mass, later identified as pheochromocytoma and resected. In 2018, he presented with bilateral leg pain, revealing metastatic disease-causing spinal cord compression along with metastatic lung nodules and metastasis in adrenalectomy bed. Despite interventions including T6,7,8 laminectomy in 2020 and radiation therapy, metastases persisted. In 2024, he presented with polyuria, polydipsia, and hyperglycemia (blood glucose &amp;gt;500 mg/dL). Laboratory findings showed elevated a1c of 15 in addition to elevated normetanephrines, metanephrines, and dopamine with levels of 3880, 48 and 488 respectively. He was diagnosed with new-onset DM and started on insulin therapy in addition to metformin and jardiance. Discussion: Secondary diabetes mellitus (DM) in secretory pheochromocytoma occurs in approximately 50% of cases, manifesting from mild insulin resistance to severe presentation like DKA. Epinephrine-secreting tumors contribute to glucose intolerance by activating beta receptors, thereby stimulating gluconeogenesis. Patients with higher levels of epinephrine and preoperative glucose intolerance were more prone to developing postoperative hypoglycemia, requiring close monitoring during the postoperative period. Additionally, research by DiSalvo et al. Epinephrine-secreting tumors have a more significant impact on hyperglycemia by impairing insulin secretion and stimulation GLP-1. Tumor resection has been found to be more effective effective in restoring normal glucose homeostasis in these patients. Dopamine-secreting pheochromocytomas are rare neoplasms characterized by the presence of immature catecholamine vesicles that inhibit dopamine conversio owing to localized dopamine beta hydroxylase. Typically presenting around the age of 48, these tumors often lack excess catecholamines, leading to atypical symptoms such as local discomfort or pain from tumor compression. These neoplasms are less detectable on metaiodobenzylguanidine (MIBG) scans, necessitating positron emission tomography (PET) for accurate diagnosis. Surgical resection is the treatment, with preoperative management involving metyrosine instead of alpha blockers. These tumors are frequently diagnosed late, often in a malignant stage, contributing to poor prognosis Conclusion: Overall, understanding the complex interplay between catecholamines and glucose metabolism is crucial for the comprehensive management of patients with pheochromocytoma and secondary DM. Presentation: 6/1/2024

A potential marker for increased LDL and hypertriglyceridemia risk

Background and objectives. Serum uric acid (SUA), traditionally associated with gout, is increasingly recognized for its potential role in cardiometabolic disorders, including dyslipidemia. Elevated SUA levels may influence lipid metabolism, thus enhancing cardiovascular disease risk. This study aims to explore the association between SUA levels, dyslipidemia, and related risk factors in a cohort of patients, contributing to a better understanding of their interplay and implications for cardiovascular health. Material and methods. We conducted a retrospective case series involving 30 participants selected from the outpatient Department of General Medicine. The study was approved by the Institutional Review Board, and informed consent was waived due to the retrospective design and use of de-identified data. Participants were aged 18 or older with available data on SUA, LDL cholesterol, and triglycerides, excluding those with a history of gout, renal impairment, or current use of urate-lowering medications. Data were analyzed using descriptive statistics, chi-square tests, and Mann-Whitney U tests, with significance set at p &lt;0.05. Results. The study population had a mean age of 54.7 ± 6.3 years and a mean BMI of 28.4 ± 2.4 kg/m². The mean SUA level was 6.9 ± 0.8 mg/dL, LDL cholesterol was 138 ± 13 mg/dL, and triglycerides were 162 ± 25 mg/dL. Dyslipidemia was present in 60% of the participants. Significant associations were found between hyperuricemia and dietary habits, family history of gout, CVD, and dyslipidemia, as well as the duration of hyperuricemia. Conclusion. Elevated SUA levels are significantly associated with dyslipidemia and other cardiovascular risk factors. The findings suggest the importance of managing SUA levels and lipid profiles concurrently to reduce cardiovascular risks. Further research is needed to explore the long-term cardiovascular outcomes of persistent hyperuricemia and dyslipidemia.

UNFORESEEN BARRIER IN GOUT TREATMENT: A CASE OF COEXISTING LYME DISEASE

Refractory gout and Lyme disease are distinct conditions that, when coexisting, pose significant diagnostic and therapeutic challenges, particularly in regions endemic for Lyme disease. This case report presents a 49-year-old male with a three-year history of gout, presenting with acute arthritis of the first metatarsophalangeal joint, unresponsive to standard urate-lowering therapy. Despite treatment with colchicine and prednisone, the patient’s symptoms persisted, and inflammatory markers remained elevated. Imaging revealed findings consistent with gouty arthritis, but due to the atypical treatment response, further testing was conducted. Serological analysis confirmed infection with Borrelia burgdorferi, establishing the diagnosis of concurrent Lyme disease. The addition of doxycycline to the treatment regimen resulted in significant clinical improvement within days. This case highlights the importance of considering Lyme disease in patients with refractory gout in areas endemic for Lyme disease. While rare cases of Lyme disease mimicking gout have been reported, this is among the first documented instances of their coexistence. Early recognition and appropriate antibiotic treatment are critical in preventing complications and ensuring optimal management of both conditions.

Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study

BackgroundUncontrolled gout can cause articular impairment but is also associated with a global and cardiovascular excess mortality, especially in dialysis population.Data documented within existing research is not conclusive regarding gout flares evolution during hemodialysis and their control by urate lowering therapy (ULT).Without clear guidelines concerning hemodialysis patients management with chronic gout, this study proposes to investigate whether gout flare incidence reduction could be observed on this population treated by urate lowering therapy versus patients without treatment.MethodsWe performed a retrospective cohort study in two hemodialysis centers in France. Were selected patients over 18 years old with a gout history who started hemodialysis between January 2005 and September 2015.Demographics and clinicals data were recorded at hemodialysis start and throughout 5 years of follow up. Gout flare was defined as presence of uric acid crystal in joint punction or clinically diagnosed as such with a colchicine prescription.All statistical analysis were performed in SAS® version 9.4 (SAS Institute Inc., Cary, NC).ResultsOne hundred eighty-one patients have been included, mean age at dialysis initiation was 68.6 years (± 12.4) with 72% of men, 54% were treated by ULT: 89.7% by allopurinol and 9.3% by febuxostat. One patient received both treatments successively. After hemodialysis initiation, 35.36% patients had experienced at least one gout flare. The appearance of at least one gout flare concerned 50% of patients in no ULT group and 22.68% patients in ULT group (p = 0.0002).Dialysis efficiency was measured at regular interval during follow-up and was similar in both groups.To study the association strength between clinical factors and gout flares occurrences, a Cox model was performed; ULT is a protector factor of gout flare (HR:0,42, CI 95: 0,25-0,71).The proportion of serum urate values within the target (median 53% vs 29.3%, p < 0.0001) was significantly higher in ULT group versus no ULT group (median 53% vs 29.3%, p < 0.0001).ConclusionUrate lowering therapy limit new gout flares occurrence in hemodialysis patients with gout historyCollaboration between rheumatologists and nephrologists may help to update guidelines for urate-lowering therapies in patients on dialysis.

The role of serum uric acid in predicting left ventricular function and outcomes in patients with STEMI following PCI

Objectives: Percutaneous coronary intervention (PCI) is the preferred treatment for ST-elevation myocardial infarction (STEMI); however, reduced left ventricular ejection fraction (LVEF) remains a critical issue post-PCI. Serum uric acid (SUA) has emerged as a biomarker linked to cardiovascular events and may be associated with LVEF. This study aims to investigate the relationship between SUA levels and LVEF in STEMI patients treated with primary PCI and identify potential biomarkers for predicting patient outcomes. Methods: This prospective study was conducted at Afshar Hospital, Shahid Sadoughi University of Medical Sciences of Yazd, from September 2019 to March 2021. Participants included 254 consecutive ST-elevation myocardial infarction (STEMI) patients undergoing primary PCI. Exclusion criteria were contraindications for angiography, history of myocardial infarction, PCI, CABG, NSTEMI, thrombolytic treatment, kidney diseases, gout, or alcoholism. Demographic data, clinical history, SUA levels, and echocardiographic parameters were collected. Statistical analysis was performed using SPSS version 20.0, with significance at p&lt;0.05. Results: 81.49% of patients were male, with a mean age of 57.7±11.47 years. Hypertension was the most prevalent condition (42.9%). SUA levels did not significantly differ between patients with LVEF below and above 40% (p=0.39). However, smoking was significantly associated with reduced LVEF (p&lt;0.001). A weak negative correlation between SUA and LVEF was observed in males (p=0.012) but not in females (p=0.097). Overall, a weak negative correlation between SUA and LVEF was statistically significant (p=0.05). Conclusions: Our findings revealed a weak but statistically significant overall negative correlation between SUA and EF. Further research with larger, more diverse populations is necessary to elucidate the relationship between SUA and cardiac function in STEMI patients.

Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study.

Hyperuricemia is frequently observed in patients with type 2 diabetes (T2D) and is associated with increased risk of gout and cardiovascular disease (CVD). Empagliflozin lowers serum urate levels by enhancing its urinary excretion. To compare initiators of empagliflozin vs dipeptidyl peptidase-4 inhibitor (DPP4i) and initiators of empagliflozin vs glucagon-like peptide-1 receptor agonist (GLP-1RA) with respect to the risk of incident gout events. Using three claims-based datasets from 08/2014 to 09/2019, we generated two cohorts (cohort 1: empagliflozin vs DPP4i; cohort 2: empagliflozin vs GLP-1RA) of adult patients with T2D and without prior history of gout or gout-specific medication dispensing separately in each dataset. To assess the risk of incident gout, we estimated hazard ratios (HR) and rate differences (RD) per 1000 person-years (PY) with their 95% confidence intervals (CI) before and after 1:1 propensity score (PS) matching adjusting for 141 baseline covariates. We identified 102,262 pairs of 1:1 propensity score-matched adults in cohort 1 and 131,216 pairs in cohort 2. Over a mean follow-up period of 8months on treatment, the risk of gout was lower in patients initiating empagliflozin compared to DPP4i (HR = 0.69: 95%CI (0.60-0.79); RD = - 2.27: 95% CI (- 3.08, 1.46)) or GLP-1RA (HR = 0.83: 95%CI (0.73-0.94); RD = - 0.99: 95%CI (- 1.66, - 0.32)). Results were consistent across subgroups (sex, age, body mass index, chronic kidney disease, heart failure, cardiovascular disease, and concurrent diuretic use) and sensitivity analyses. Among adults with T2D, the initiation of empagliflozin vs a DPP4i or GLP-1RA was associated with lower risk of incident gout, complementing results from a post hoc analysis of the EMPA-REG OUTCOME trial and previously published observational research focusing on the sodium-glucose co-transporter-2 inhibitor class in more narrowly defined study populations.

ASUHAN KEPERAWATAN GERONTIK PADA PASIEN OSTEOPOROSISDENGAN MASALAH KEPERWATAN NYERI KRONIS MENGGUNAKAN TERAPI SENAM OSTEOPOROSIS DI UPT PSTW JOMBANG

Elderly people who experience musculoskeletal pain include elderly people with a history of gout, rheumatism, osteoporosis, osteoarthritis, lower back pain and muscle pain. There have been many methods used to overcome this pain, such as drinking warm water and taking pain medication, but these have not provided optimal results. Implement Gerontik Nursing Care for Osteoporosis Patients With Chronic Pain Nursin Problems at UPT PSTW Jombang. The design of this research is a case study using 2 osteoporosis clients with chronic pain nursing problems, who received nursing care for 7 consecutive days using an intervention, namely Osteoporosis Gymnastics therapy. The results of the study showed that the problem of chronic pain by providing Osteoporosis Exercise therapy, the problem was resolved in reducing the pain level of the elderly. Osteoporosis Exercise Therapy can help reduce pain and provide comfort to the elderly, this therapy is carried out for 7 days.

Controversies and practical management of patients with gout and chronic kidney disease

Uric acid is a toxin retained with advancing kidney disease. Clinical manifestations of hyperuricemia include gout and systemic inflammation that are associated with increased risk for cardiovascular mortality. As many as one third of all patients with chronic kidney disease (CKD) have a history of gout, yet <25% of these patients are effectively treated to target serum urate levels of ≤6 mg/dL. A major reason for ineffective management of gout and hyperuricemia is the complexity in managing these patients, with some medications contraindicated, others requiring special dosing, potential drug interactions, and other factors. Consequently, many nephrologists do not primarily manage gout despite it being a common complication of CKD, leaving management to the primary physician or rheumatologist. We believe that kidney specialists should consider gout as a major complication of CKD and actively manage it in their patients. Here, we present insights from nephrologists and rheumatologists on a team approach to gout management that includes the nephrologist.

Autosomal-dominant tubulointerstitial kidney disease with a novel UMOD mutation, overlapping with Sjogren's syndrome: a case report.

Autosomal-dominant tubulointerstitial kidney disease caused by UMOD (encoding uromodulin) mutation (ADTKD-UMOD) is a rare hereditary disease. A strong family history of hyperuricemia or gout and inherited kidney disease raises the suspicion of ADTKD-UMOD. Genetic testing can confirm the diagnosis without a kidney biopsy. However, when complicated by other diseases that can cause tubulointerstitial disease, renal biopsy is indispensable for the diagnosis and decisions on treatment strategy. We report the case of a 44-year-old woman referred for evaluation of kidney dysfunction. She had an attack of gout 1month before referral and a family history of hyperuricemia. She was diagnosed with primary Sjogren's syndrome through an immune workup and ophthalmological examination. However, a kidney biopsy revealed histological features suggesting ADTKD rather than gouty kidney or tubulointerstitial nephritis associated with Sjogren's syndrome, and immunostaining revealed a characteristic staining pattern with UMOD. Comprehensive genetic testing of 93 genes responsible for polycystic kidney disease revealed a novel heterozygous missense variant (c.649T > A:p. Cys217Ser) in UMOD, and the patient was diagnosed with ADTKD-UMOD. In this case, kidney biopsy contributed to the correct diagnosis of tubulointerstitial kidney disease. This case emphasizes the importance of suspecting ADTKD-UMOD based on family history and careful evaluation of kidney biopsy findings.

Incidence and Progression of Foot Osteoarthritis in a Longitudinal Cohort: The Johnston County Osteoarthritis Project

Introduction: The aim of this study was to examine the incidence and progression of foot osteoarthritis (OA), as well as associated factors, in a community-based cohort. Methods: Baseline (2013–2015) and follow-up (2016–2018) foot radiographs were available for 541 participants (71% women, mean age 69 years; 35% black, 53% with obesity). The LaTrobe Foot Atlas was used to examine osteophytes (OPs, score 0–3) and joint space narrowing (JSN, score 0–3) at 5 joint sites. Incident foot radiographic OA (rOA) was a baseline score <2 OP and JSN in all 5 joints with ≥2 OP or JSN at follow-up in any of the joints. Progression was a worsening OP or JSN score in a joint with baseline foot rOA. At baseline and follow-up, participants reported the presence/absence of foot symptoms and completed the Foot and Ankle Outcome Score (FAOS) for each foot. Joint-based logistic regression models with generalized estimating equations were used to examine associations (adjusted odds ratio [aOR], 95% confidence interval [CI]) of foot rOA incidence and progression and with covariates. Results: Among 928 feet without baseline rOA, 4% developed incident foot rOA (2% of those developed symptoms). Among 154 feet with baseline foot rOA, 55% had radiographic progression (16% of those had symptoms). Women and those with higher body mass index (BMI) were more likely to have incident foot rOA (aOR [95% CI] = 4.10 [1.22, 13.8] and 1.60 [1.31, 1.97], respectively); history of gout was associated with incidence or progression of foot rOA (2.75 [1.24, 6.07]). BMI was associated with worse scores on all FAOS subscales (aORs range 1.21–1.40). Conclusion: Progression of foot rOA is common but not necessarily related to worsening symptoms. BMI may be a modifiable risk factor for foot OA.

Concomitant septic and crystal arthropathy: a single-centre 10-year retrospective observational study in New Zealand.

To quantify and characterise patients with coexistent septic arthritis (SA) and crystal arthritis (CA) (SACA) in an emergency department (ED) setting. A single-centre, retrospective, 10-year observational study was conducted at a major referral centre. Patients with a positive joint aspirate for CA or SA carried out in ED, were included. The Newman criteria were utilised to define SA. Of the 567 patients included in the final analysis, 427 had CA and 140 had a final diagnosis of SA. Twenty-three point six percent of patients diagnosed with SA had concomitant CA, while 7.2% of patients diagnosed with CA had concomitant SA. The greatest predisposing factors for SACA were previous history of gout, rheumatoid arthritis, being immunocompromised or having joint metalware. Synovial fluid (SF) white cell count (WCC) showed excellent predictive capability for joint infection with the area under the receiver operating characteristic curves (AUROCs) of 0.81 and 0.87 for SA and SACA respectively. The receiver operating characteristic curves (ROCs) reported a SF WCC cutoff of 32,000/mm3 allowed for 100% sensitivity and approximately 50% specificity. SACA remains a small but important sub-group of patients at risk of misdiagnosis of CA alone. SF WCC of 32,000/mm3 may be a better cutoff than the traditionally accepted 50,000/mm3, possibly warranting inpatient admission for investigation and management of presumed SA.

Establishment and validation of prediction model for atherosclerotic cardiovascular disease in patients with hyperuricemia.

To construct a risk prediction model for atherosclerotic cardiovascular disease (ASCVD) in patients with hyperuricemia. Data in this study were obtained from the National Health and Nutrition Examination Survey (NHANES) (2007-2010). Participants from Huashan Hospital were included as an external validation. Logistic regression analysis was used to explore the relevant factors of ASCVD in patients with hyperuricemia. The discriminability of the model was evaluated using the area under the curve (AUC) statistic of the receiver operating characteristic curve. Hosmer-Lemeshow test, correction curve and decision curve analysis (DCA) were used to evaluate the model. A total of 389 patients collected from the NHANES were included in the final analysis. Logistic regression analysis showed that age, creatinine (Cr), glucose (Glu), serum uric acid (SUA), and history of gout were predictive factors for ASCVD in hyperuricemia (HUA) patients. These predictive factors were used to construct a nomogram. And 157 patients from NHANES were in the internal validation group and 136 patients from Huashan Hospital were in the external validation group. The AUC values of the three groups were 0.943, 0.735, and 0.664. The p values of the Hosmer-Lemeshow test were .568, .600, and .763. The calibration curve showed consistency between the nomogram and the actual observed values. The DCA curve indicated that the model has good clinical practicality. This study constructed the ASCVD risk prediction model for HUA patients, which is beneficial for medical staff to detect high-risk populations of ASCVD in the early stage.

Association of Gout with Head and Neck Cancer: Longitudinal Follow-Up Studies Using a National Health Insurance Database in South Korea.

Objective: Previous studies have reported controversial results on the association between gout and the risk of cancer. This study aimed to investigate the relationship between gout and the incidence of head and neck cancer (HNC). Methods: The data of participants who underwent health checkups in 2009 were analyzed using the National Health Insurance Database in South Korea. A total of 14,348 HNC patients and 57,392 control participants were analyzed for a prior history of gout. Overlap weighting was applied, and odds ratios (ORs) of gout for HNC patients were analyzed. The overlap-weighted model adjusted for demographic, socioeconomic, and lifestyle factors and comorbidities. HNC sites were classified as oral cavity cancer, oropharyngeal cancer, nasopharyngeal cancer, hypopharyngeal cancer, nasal cavity/sinus cancer, larynx cancer, or salivary gland cancer, and the ORs of gout were estimated for each site. Results: Overall, patients with HNC had 1.12-fold greater odds of having gout (95% confidence intervals [CIs] = 1.04-1.20). According to the site of HNC, oral cavity cancer, oropharynx cancer, and larynx cancer demonstrated high odds of having gout (OR = 1.25, 95% CI = 1.16-1.34 for oral cavity cancer; OR = 1.08, 95% CI = 1.01-1.15 for oropharynx cancer; and OR = 1.12, 95% CI = 1.06-1.20 for larynx cancer). On the other hand, nasal cavity/sinus cancer, nasopharynx cancer, and salivary gland cancer presented low odds of having gout (OR = 0.78, 95% CI = 0.72-0.84 for nasal cavity/sinus cancer; OR = 0.89, 95% CI = 0.83-0.96 for nasopharynx cancer; and OR = 0.88, 95% CI = 0.81-0.96 for salivary gland cancer). Conclusions: A prior history of gout was associated with a high overall incidence of HNC. Oral cavity cancer, oropharynx cancer, and larynx cancer have a high incidence in gout patients. However, nasal cavity/sinus cancer, nasopharyngeal cancer, and salivary gland cancer have low incidences in gout patients. The impact of gout on HNC risk should be specifically considered according to the site of the HNC.

Meta-analysis and systematic review of gout prevalence in the heart/lung transplantation population.

Gout may complicate solid organ transplantation with potentially serious consequences. An accurate prevalence of gout in this population is unknown. This study aimed to estimate the prevalence of gout in the heart and/or lung transplantation population through a systematic review and meta-analysis. MEDLINE, Embase, PsycINFO, CENTRAL and Cochrane Library (inception to February 2022) were searched for studies that reported the prevalence and/or incidence of gout in heart and/or lung transplant recipients. Two authors extracted outcomes data. Data were pooled using a random effects model. Overall quality of evidence was assessed using GRADE. Primary outcomes were the prevalence of pre- or post-transplant gout expressed as a prevalence rate (95% CI). Secondary outcomes included risk factors for gout, adverse events, and therapeutic complications of gout treatment. Ten studies were included. Gout prevalence (PR) was 8% pre-transplant (PR = 0.08; 95% CI: 0.05-0.12; 4 studies n = 651) and 6% post-transplant (PR = 0.06; 95% CI: 0.06-0.06; 10 studies n = 45,298). Post-transplant gout prevalence in heart transplant recipients was almost three times higher than lung transplant recipients (PR = 0.16; 95% CI: 0.13-0.20 vs. PR = 0.06; 95% CI: 0.05-0.06 respectively). Patients with a pre-transplant history of gout had a higher risk of developing post-transplant gout than patients without (RR = 3.61; 95% CI: 2.19-5.95). Factors associated with gout and outcomes for heart and/or lung transplant recipients with gout were comprehensively reviewed from the included studies. Gout is highly prevalent in heart and/or lung transplant patients. Pre-transplant gout is predictive of developing symptomatic post-transplant gout. This has significant implications for management of heart/lung transplant patients. https://www.crd.york.ac.uk/, PROSPERO (CRD42020190632).

A Complex Case of Colchicine-Induced Myopathy and Polyarticular Gout in a Patient with Chronic Kidney Disease

Colchicine, a medication commonly used for the treatment of gout and other inflammatory conditions, is known to cause various adverse effects, including myopathy. We present a case of colchicine-induced myopathy in a 58-year-old male with a history of gout. The patient developed progressive muscle weakness after initiating colchicine therapy. Prompt discontinuation of colchicine resulted in resolution of symptoms and normalization of muscle enzyme levels. This case underscores the importance of recognizing colchicine-induced myopathy and prompt discontinuation of the medication to prevent further complications and report also highlights the challenges and considerations in managing a patient with multiple comorbidities and the importance of close follow-up and ongoing monitoring. Keywords: Colchicine, Myopathy, Gout, Adverse effects, Muscle weakness